Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial

Giugliano, Robert; Keech, Anthony; Murphy, Sabina; Huber, Kurt; TOKGÖZOĞLU, SADBERK; Lewis, Basil; Ferreira, Jorge; Pineda, Armando; Somaratne, Ransi; Sever, Peter; Pedersen, Terje; Sabatine, Marc

doi:10.1001/jamacardio.2017.3944

Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial

Giugliano R. P., Keech A., Murphy S. A., Huber K., TOKGÖZOĞLU S. L., Lewis B. S., ...Daha Fazla

JAMA CARDIOLOGY, cilt.2, sa.12, ss.1385-1391, 2017 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 2 Sayı: 12
Basım Tarihi: 2017
Doi Numarası: 10.1001/jamacardio.2017.3944
Dergi Adı: JAMA CARDIOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1385-1391
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Hacettepe Üniversitesi Adresli: Evet

Özet

IMPORTANCE Current guidelines for atherosclerotic cardiovascular disease focus on high-intensity statins and targeting or using a threshold low-density lipoprotein cholesterol (LDL-C) level of less than 70 mg/dL for the highest-risk patients. Whether further reduction of LDL-C beyond these boundaries would be beneficial is unknown.